Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Trillium Therapeutic (TRIL)

18.44   0 (0%) 01-19 09:07
Open: 17.92 Pre. Close: 18.44
High: 18.49 Low: 17.83
Volume: 26,174,709 Market Cap: 1,936M
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 18.533 - 18.624 18.624 - 18.698
Low: 17.58 - 17.703 17.703 - 17.803
Close: 18.264 - 18.454 18.454 - 18.608

Technical analysis

as of: 2022-01-19 8:55:52 AM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 21.60     One year: 25.22
Support: Support1: 18.08    Support2: 17.83
Resistance: Resistance1: 18.49    Resistance2: 21.60
Pivot: 18.44
Moving Average: MA(5): 18.44     MA(20): 18.44
MA(100): 17.98     MA(250): 13.08
MACD: MACD(12,26): 0.03     Signal(9): 0.04
Stochastic oscillator: %K(14,3): 92.42     %D(3): 92.42
RSI: RSI(14): 73.35
52-week: High: 18.49  Low: 5.80  Change(%): 40.4
Average Vol(K): 3-Month: 1861749  10-Days: 2617471

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
TRIL has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to TRIL's normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 16 Nov 2021
Trillium Therapeutics gains quickly after Nasdaq delisting notice on Pfizer deal - Seeking Alpha

Thu, 28 Oct 2021
Trillium Therapeutics Receives Final Court Order Approving Arrangement - Yahoo Finance

Mon, 23 Aug 2021
Why Trillium Therapeutics Stock Is Skyrocketing Today - Motley Fool

Fri, 13 Aug 2021
Trillium Therapeutics Reports Second Quarter 2021 Operating - GlobeNewswire

Mon, 09 Aug 2021
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia - GlobeNewswire

Tue, 13 Jul 2021
Hedge Funds Are Selling Trillium Therapeutics Inc. (TRIL) - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 105
Shares Float (M) 87
% Held by Insiders 5.47
% Held by Institutions 81.82
Shares Short (K) 2,310
Shares Short P. Month (K) 2,810

Stock Financials

EPS -0.500
EPS Est This Year -4.130
EPS Est Next Year -2.740
Book Value (p.s.) 2.330
Profit Margin
Operating Margin -118641.86
Return on Assets (ttm) -15.6
Return on Equity (ttm) -29.9
Qtrly Rev. Growth -91.3
Gross Profit (p.s.) 0.001
Sales Per Share
EBITDA (p.s.) -0.482
Qtrly Earnings Growth
Operating Cash Flow (M) -38
Levered Free Cash Flow (M) -19

Stock Valuations

PE Ratio -36.88
PEG Ratio
Price to Book value 7.91
Price to Sales 45027.91
Price to Cash Flow -51.39

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.